A word from the CEO
”2023 has proven to be a successful year for AroCell. We have observed consistent strong demand in both our bacteriology and oncology segments, with sales in these areas reaching record levels. We have significantly increased our collaboration in automation and are on the verge of introducing several biomarkers onto automated platforms in China.
 
Several studies were completed throughout the year that helped improve our products market standing. We have optimized our organization, and with a rise in product demand, we are now closer to achieving positive cash flow. We are experiencing ongoing, consistent growth and a rising order intake that we are now able to manage effectively. I am eagerly anticipating further growth in 2024.
 
Nevertheless, the fourth quarter of 2023 could have been more successful. Some sales from the end of last year were delayed to 2024 due to issues with subcontractors and transportation. These delays caused a potential loss in turnover of 4 MSEK in 2023. However, of this, 2 MSEK has been recovered in January 2024.”
 
Anders Hultman, CEO
 
Reporting period October 1st – December 31st
· Net sales amounted to KSEK 9,511 (12,471).
· Profit after financial items amounted to KSEK -17,136 (-16,520)*.
· Cash flow from operating activities for the period amounted to KSEK -912 (-2,321).
· Earnings per share before and after dilution amounted to SEK -0.07 (-0.07).
· Cash and cash equivalents at the end of the period amounted to KSEK 50,723 (65,189).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
 
Reporting period January 1st – December 31st
· Net sales amounted to KSEK 43,039 (36,986).
· Profit after financial items amounted to KSEK -59,297 (-59,299)*.
· Cash flow from operating activities for the period amounted to KSEK -13,436 (-13,694).
· Earnings per share before and after dilution amounted to SEK -0.26 (-0.28).
· Cash and cash equivalents at the end of the period amounted to KSEK 50,723 (65,189).

* Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.
 
Events during the period October 1st – December 31st
· After the conclusion of the period, the warrant program has been implemented. The total number of warrants issued is 5,000,000, with a premium of 0.05 öre. The program has a duration of 3 years and is allocated among various groups, including the CEO, management team, other executives, and other employees. The strike price has been set at SEK 1, and the warrants are subscribed on market terms.

· AroCell presented information on the nomination committee’s proposal prior to the 2024 annual general meeting.
 
Events after the period
· A recent study has shown that serum thymidine kinase 1 (sTK1) levels can predict the survival of patients with metastatic prostate cancer. The results also suggest that sTK1 is useful in predicting which patients may benefit from chemotherapy with the drug docetaxel instead of a hormonal treatment. 

· Previously, AroCell announced a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sales of TUBEX® TF in Ethiopia. After navigating through the local regulatory process, AroCell has now obtained regulatory approval for TUBEX® TF in Ethiopia. 

· Ellen Dittberner, who serves as the CFO at AroCell, is currently on parental leave, and Lars Jakobsson has stepped in as the acting CFO.
 
Interim report January 1st – December 31st, 2023 (Link)